ArticleTranslational cancer research2021
Identification of prognostically relevant gene signatures in lung squamous cell carcinoma by Lung Cancer Explorer.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiological features and key genes are urgently needed to reveal the transcriptomic landscape and guide diagnosis and therapy for lung squamous cell carcinoma (LUSC). However, most papers have only focused on highly expressed genes correlated with poor survival in LUSC, which limits the understanding of this cancer type.
methodsMeta-analysis results of genes with tumour-normal differential expression and survival association in LUSC patients provided by the web-tool Lung Cancer Explorer (LCE) were used to determine the differentially expressed genes (DEGs) and prognostically relevant genes (PRGs); the intersected genes were divided into groups, and their biological functions were explored by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The network of each group was visualized, and the top-ranked genes were selected by the 'degree' method and further tested for their survival association using the Kaplan-Meier (KM) Plotter web tool. Paired cancer and adjacent tissues from LUSC patients were used to confirm the differential expression.
resultsA total of 506 genes, as both DEGs and PRGs, were categorized into 4 gene signatures representing distinct biological features, including regulation of the immune system, epithelium development, small GTPase-mediated signal transduction, Adenosine diphosphate (ADP) metabolic process, and glycolysis. Finally, 9 hub genes were identified and subsequently retested to be correlated with survival through univariate and multivariate Cox regression analyses in KM plotter. Paired clinical samples validated the changes in mRNA expression of
conclusionsThis study provides more insight into the functional and molecular features of LUSC through meta-analysis of available data and identifies therapeutic and diagnostic markers for LUSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.